Tags:DevelopmentEstateLifeProductPropertyResearch
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.
Location: United States, San Diego
Total raised: $155.5M

Investors 2

Funding Rounds 4

DateSeriesAmountInvestorsDeal News
21.11.2016-$20M--
01.04.2015Series E$76M-aTyr Pharm...
29.07.2013-$49M--
18.04.2007-$10.5M--

Mentions in press and media 9

DateTitleDescriptionCategoryAuthorSource
21.11.2016 aTyr P...San Diego-based biotherapeutic...--socaltech....
29.06.2016The biotec...There was a time af­ter the 2...FinancingJohn Carro...endpts.com...
01.04.2015aTyr Pharm...aTyr Pharma, Inc., a San Diego...USA-finsmes.co...
01.04.2015 aTyr P...San Diego-based biopharmaceuti...--socaltech....
01.04.2015aTyr raise...--medcitynew...
29.07.2013 aTyr P...San Diego-based aTyr Pharma, a...--socaltech....
29.07.2013aTyr Pharm...aTyr Pharma, a San Diego CA-ba...funding S...-finsmes.co...
26.10.2010aTyr Pharm...aTyr Pharma, a San Diego CA-ba...funding v...-finsmes.co...
18.04.2007 aTyr P...San Diego-based aTyr Pharma, a...--socaltech....